Evidence map›Paper›PMID 41565833›Full record

ArticleJournal of bone and mineral metabolism2026

Identifying the clinical indicator for surgical intervention in medication-related osteonecrosis of the jaw.

Yoshiaki Tadokoro, Takumi Hasegawa, Daisuke Takeda, Junya Hirota, Kaito Uryu, Tatsuya Shirai, Yumi Muraki, Masaya Akashi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bone and mineral metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yoshiaki TadokoroDepartment of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan. tadokoro-yoshiaki@med.kobe-u.ac.jp.ORCID http://orcid.org/0000-0002-8079-1484
Takumi HasegawaDepartment of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.
Daisuke TakedaDepartment of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.
Junya HirotaDepartment of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.
Kaito UryuDepartment of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.
Tatsuya ShiraiDepartment of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.
Yumi MurakiDepartment of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.
Masaya AkashiDepartment of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSurgery has increasingly been reported as an effective treatment for medication-related osteonecrosis of the jaw (MRONJ), but concrete intervention criteria are lacking. On computed tomography (CT) images, the boundary between the healthy site and necrotic lesion, which we defined as "MRONJ demarcation line", is sometimes visible. This study aimed to identify the factors associated with this boundary to improve surgical planning. MATERIALS AND

methods95 patients with MRONJ who underwent their first CT at our institution between May 2010 and June 2022 were included. The Mann-Whitney U test, Fisher's exact test, and multivariate logistic regression analysis were performed. The cumulative incidence rates were calculated using the Kaplan-Meier method. Statistical significance was set at p < 0.05.

resultsMRONJ demarcation line was observed in 63 patients and absent in 32. Significant associations were identified between MRONJ demarcation line formation and denosumab (p = 0.013), antiresorptive agent (ARA) discontinuation (p = 0.024), and periosteal reaction ( p = 0.034). The cumulative incidence rates of MRONJ demarcation line formation at 12, 24, and 36 months after discontinuation of high-dose ARA were 58.0%, 89.2%, and 96.4% for denosumab, and 29.9%, 68.8%, and 88.3% for bisphosphonates, respectively. In the low-dose group, the rates at 12, 24, and 36 months after discontinuation of denosumab were 41.7%, 51.4%, and 63.5%, respectively, while those for bisphosphonates were 22.2%, 35.8%, and 51.1%.

conclusionDenosumab administration, ARA discontinuation, and periosteal reaction are significantly associated with the MRONJ demarcation line, which may help in establishing criteria for surgical intervention.

Indexed as

Bisphosphonate-Associated Osteonecrosis of the JawAgedBone Density Conservation AgentsDenosumabFemaleHumansMaleMiddle AgedRetrospective StudiesTomography, X-Ray ComputedBone Density Conservation AgentsDenosumabComputed tomographyDemarcation lineMedication-related osteonecrosis of the jawTreatment strategy

Identifiers

PMID41565833
PMCPMC13246828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.